Spine BioPharma Announces Topline Results from Phase 3 MODEL Trial For SB-01
A single intradiscal injection of SB-01 in CLBP patients associated with DDD demonstrated:
A robust safety profile consistent with the previous Phase 2 study.
SB-01 patients saw a numerical and clinically meaningful improvement in pain intensity and pain-related function.
The SB-01 response was observed at all timepoints out to Month 6 and was durable at one year.
There was no difference in success at any timepoint between 1- and 2-level patients.
There was an inconsistent sham control response among sites, with some sites having much higher than anticipated sham control rates.
In sites with an anticipated sham control response, SB-01 outperformed the sham control, almost achieving nominal statistical significance p=0.051.
The clinical trial was prospective, 1:1 randomized with 417 patients utilizing a single 1.5 ml intradiscal injection of SB-01 or a sham control. Both 1- and 2-level DDD patients were enrolled across 30 sites in the United States. Patients were followed at Week 2, Week 6, Month 3 and to the primary endpoint at Month 6 with an additional follow-up at Month 12. Patients were evaluated for pain intensity utilizing Numerical Rating Scale (NRS) and pain-related function using Oswestry Disability Index (ODI). Patients had to achieve both a 2/10-point improvement in NRS and 15/100-point improvement in ODI to be considered an overall composite success (primary endpoint).
As previously observed in the Phase 2 clinical trial of 325 patients, and in this Phase 3 clinical trial of 417 patients, SB-01 demonstrated a robust safety profile.
In the Intent-to-Treat (ITT) analysis of the 417 patients, the SB-01 group achieved primary endpoint success (ODI+NRS) of 67% at Month 6, which although clinically meaningful, did not reach statistical significance compared to the sham control group. The SB-01 response was present at the early timepoints. For the patients that reached the Month 12 follow-up at database lock (N=281), 62% of the SB-01 group achieved composite success (ODI+NRS). There was no difference in SB-01 success at any timepoint between 1- and 2-level patients.
In a secondary endpoint ITT analysis of pain-related function (ODI), the SB-01 group achieved a clinically meaningful success rate of 75% at Month 6, and 71% at Month 12 but was not statistically significant compared to the sham control.
Fran Magee, DVM, CTO, stated 'The SB-01 patients responded as anticipated and consistent with the Phase 2 study. In contrast, the sham control response was statistically significantly higher than observed in the Phase 2 study. The statistical design of this Phase 3 study anticipated a high sham control success, as observed in the Phase 2 study and typically seen in CLBP studies. We are surprised by the very high sham control response in this study that kept us from achieving statistical significance.'
In this Phase 3 study, the very high sham response was not observed at all investigational sites. There is statistically reliable evidence of site-to-site heterogeneity in the sham control response with some sites demonstrating exceedingly high sham control response that was not observed in the homogenous SB-01 response across sites.
Given the site-to-site sham control response variability, a subset analyzing only patients (n=227) at sites that had an anticipated sham response, consistent with the previous Phase 2 study was performed. For the ITT analysis, utilizing the composite primary endpoint (ODI+NRS) the response in the SB-01 and sham control group was 70% and 59% respectively, nominal p=0.051. In the same patient subset, the secondary endpoint of ODI response in the SB-01 and sham control group was 79% and 69% respectively and compared to sham control with a nominal p=0.040. These analyses demonstrate that in the sites that had the anticipated sham control response rate, SB-01 outperformed the sham control patients.
Marc Viscogliosi, CEO, stated 'Despite our disappointment in missing the primary endpoint, we are quite proud of enrolling and completing this trial under strict FDA guidelines. We ran a solid trial and had we achieved our anticipated sham control group response, the results would have been statistically significant in favor of SB-01.'
Christopher Gilligan, MD, Principal Investigator of the MODEL trial stated 'This was a landmark, well-designed clinical trial with strict enrollment criteria and very high follow-up rates. The study employed a rigorous composite endpoint requiring patients to achieve both clinically meaningful improvement in both pain intensity and pain-related function. Pain studies are challenging and are susceptible to a sham control response, which was particularly high in this study. We are thankful to the patients, their families, investigators, clinical coordinators, and research associates who participated in this clinical trial for CLBP.'
There remains a significant need for less invasive, safe and effective treatment for CLBP associated with DDD. Spine BioPharma will complete the data analysis. We plan to meet with the FDA to discuss the results from this Phase 3 trial together with the earlier Phase 1 and 2 randomized trials and explore potential approval pathways for SB-01 as a treatment for CLBP associated with moderate-severe DDD.
About the MODEL Clinical Trial
SB-01 MODEL clinical trial is a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 trial being conducted to establish the safety and effectiveness of SB-01 For Injection in adult patients with chronic low back pain and its associated impairment in pain-related function due to Lumbar DDD.
About SB-01 For Injection
SB-01 is a 7-amino acid synthetic peptide that binds to and antagonizes TGF-Beta activity. TGF-Beta is a pleiotropic cytokine expressed by almost every tissue and cell type, is stored in abundance in the extracellular matrix, and possesses suppressive and stimulatory signaling pathways. In many diseases, there are high concentrations of TGF-Beta that result in a spectrum of negative downstream effects including inflammation, fibrosis, neoinnervation, hyperexcitability of nerves and cell proliferation. SB-01 modulates TGF-Beta concentration, without eliminating it, mitigating the negative downstream effects.
About Spine BioPharma
Spine BioPharma is committed to developing non-opiate, non-surgical treatments that will reduce pain, restore function, and slow or stop pathological disease progression. Spine BioPharma's lead candidate, SB-01 For Injection, is a first-in-class treatment of DDD, offering potential clinical benefits of pain relief, restoration of function, and prevention of disease progression. To learn more about Spine BioPharma, visit www.spinebiopharma.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 minutes ago
- Business Wire
Molina Healthcare of Illinois Invests $1.6 Million to Improve Access to Health Care
CHICAGO--(BUSINESS WIRE)-- Molina Healthcare of Illinois ('Molina'), in collaboration with The MolinaCares Accord ('MolinaCares'), is announcing over $1.6 million in support of local community organizations to improve health outcomes in Illinois. "Through our partnership with Molina, PRISM is expanding the reach of our mobile immunization program, ensuring children across Chicagoland get the vaccines and preventive care they need to stay healthy,' said Zul Kapadia, president of PRISM Health. 'Molina's support allows us to bring our mobile clinic to 40 more schools and community sites, while helping us retain the health care workers who make this work possible. We're meeting families where they are and delivering care right to their doorstep." Together with community partners, Molina is working to enhance and create programs designed to address community health needs, increase access to care, improve behavioral health and maternal health outcomes, strengthen the health care workforce, and support families in Illinois. 'Molina is dedicated to ensuring everyone, regardless of their circumstances, has access to the care and resources they need,' said Matt Wolf, plan president of Molina Healthcare of Illinois. 'These investments are designed to address health disparities by helping trusted community partners carry out their missions to improve access and health outcomes for our communities.' Access to Care In Illinois, nearly 17% of adults reported having no usual source of medical care. Furthermore, across Illinois, only 28.5% of residents received a flu shot while 21.5% of children ages 5-17 received a flu shot. Molina is committed to bridging gaps by bringing care directly to individuals who need it, helping increase vaccine rates and improve health outcomes. Through this investment, Molina is supporting a mobile health program, enhancing immunization access for both adults and children, and bringing vaccines directly to schools. Behavioral Health Illinois faces significant and persistent gaps in its behavioral health system, with nearly 40% of Illinoisans living in a designated mental health professional shortage area. To address the shortage of behavioral health care, Molina is supporting initiatives that enable uninsured and underinsured individuals to access mental health care and increase the capacity of local providers to deliver care. Maternal Health Molina is committed to improving maternal health and addressing disparities so that mothers and babies can have a healthy start. Black women are more than twice as likely to die from a pregnancy-related condition and three times more likely to die from pregnancy-related medical conditions than white women. Molina is investing in initiatives to improve maternal health outcomes by increasing access to doulas, which have been shown to lower rates of cesarean delivery, reduce the risk of preterm birth, and increase postpartum visits. Health-Related Social Needs Data shows that health-related social needs, including housing, food, transportation, and economic security play a critical role in shaping health outcomes for individuals and communities. Molina's partnerships aim to address social needs that impact health by supporting free laundry services, increasing access to food, and improving housing stability. Workforce Development Molina's partnerships aim to enhance the provider workforce in communities across Illinois by providing education and training opportunities for providers and supporting programs that are building a sustainable pipeline of physicians. Approximately 89 of Illinois' 102 counties are designated as health professional shortage areas, disproportionately impacting low-income and rural residents. About The MolinaCares Accord Established by Molina Healthcare, Inc., The MolinaCares Accord oversees a community investment platform created to improve the health and well-being of disadvantaged populations by funding meaningful, measurable, and innovative programs and solutions that improve health, life, and living in local communities. The MolinaCares Accord funds such measures through the Molina Healthcare Charitable Foundation, a 501(c)(3) established in 2020 by Molina Healthcare, Inc. About Molina Healthcare of Illinois Molina Healthcare of Illinois, Inc. provides government-funded, quality health care, serving members through Medicaid, Medicare, and Marketplace programs in Illinois. Through its locally operated health plans, Molina Healthcare, Inc., a Fortune 500 company, provides managed health care services under the Medicaid and Medicare programs, and through state insurance marketplaces. For more information about Molina Healthcare of Illinois, visit
Business Wire
5 minutes ago
- Business Wire
Angel Oak Mortgage REIT, Inc. Reports Second Quarter 2025 Financial Results
ATLANTA--(BUSINESS WIRE)-- Angel Oak Mortgage REIT, Inc. (NYSE: AOMR) (the 'Company,' 'we,' and 'our'), a leading real estate finance company focused on acquiring and investing in first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 and Year-to-Date Highlights Q2 2025 GAAP net income of $0.8 million, or $0.03 per diluted share of common stock. Q2 2025 net interest income of $9.9 million demonstrates an increase of 5.0% versus Q2 2024 net interest income of $9.5 million and a slight decrease of 1.5% compared to Q1 2025 net interest income of $10.1 million. Net interest income of $20.0 million for the six months ended June 30, 2025, an increase of 11% compared to the six months ended June 30, 2024. GAAP book value of $10.37 per share of common stock and economic book value of $12.97 per share of common stock as of June 30, 2025, decreases of 3.1% and 3.3%, respectively, from March 31, 2025. Q2 2025 Distributable Earnings of $2.6 million, or $0.11 per diluted share of common stock. Declared a dividend of $0.32 per share of common stock, which will be paid on August 29, 2025, to common stockholders of record as of August 22, 2025. Sreeni Prabhu, Chief Executive Officer and President of Angel Oak Mortgage REIT, Inc., said "The second quarter of 2025 was an active one for AOMR, as we completed two securitizations in addition to issuing $42.5 million of senior unsecured notes in May. These transactions are designed to support our strategic goal of earnings growth through accretive capital markets participation and diligent capital deployment. We quickly deployed the capital from this quarter's senior unsecured notes issuance into high-quality, current market coupon non-QM loans and other target assets." He continued, "As such, we expect to resume our quarterly sequential net interest income growth in the next quarter, as demonstrated with 2024's senior unsecured notes issuance. As always, we will remain committed to growing long-term shareholder value through disciplined risk management, securitization execution, and strategic capital deployment.' Portfolio and Investment Activity In April 2025, the Company issued AOMT 2025-4, a $284.3 million scheduled unpaid principal balance securitization backed by a pool of residential mortgage loans. We issued AOMT 2025-4 as the sole participant in the securitization. We used the proceeds to repay outstanding debt of approximately $242.4 million, and the $24.7 million of cash released was used for new loan purchases and operational purposes. In May 2025, we participated in AOMT 2025-6, an approximately $349.7 million scheduled unpaid principal balance securitization backed by a pool of residential mortgage loans, to which we contributed loans with a scheduled principal balance of $87.2 million. We used the proceeds of the securitization to repay outstanding debt of approximately $73.1 million, and retained bonds of $8.1 million. The securitization released $9.2 million of cash, which was used for operational purposes. We participated in this securitization alongside other Angel Oak entities. During the quarter ended June 30, 2025, the Company purchased $146.6 million of newly-originated, current market coupon non-QM residential mortgage loans and home equity lines of credit ("HELOC"), with a weighted average coupon of 8.68%, a weighted average combined loan-to-value ratio (or 'CLTV', calculated as the primary or first lien mortgage loan amount plus any additional borrowings secured by the property, such as a HELOC, divided by the estimated value of the property) of 68.4% and a weighted average credit score of 757. As of June 30, 2025, the weighted average coupon of our residential whole loans portfolio was 8.37%, marking a 66 basis point increase compared to June 30, 2024. Capital Markets Activity In May 2025, we closed an underwritten public offering and sale of, and issued, $42.5 million in aggregate principal amount of our 9.750% Senior Notes due 2030 (the '2030 Notes'). The 2030 Notes bear interest at a rate of 9.750% per annum. After deducting the underwriting discount and other debt issuance costs, we received net proceeds of approximately $40.6 million. We used the majority of the net proceeds from the offering for general corporate purposes, which included the acquisition of non-QM loans and other target assets in a manner consistent with our strategy and investment guidelines. As of June 30, 2025, the Company was a party to three loan financing lines which permit borrowings in an aggregate amount of up to $1.1 billion, of which approximately $118.6 million is drawn, leaving capacity of approximately $931.4 million for new loan purchases. Balance Sheet Target assets totaled $2.5 billion as of June 30, 2025. The Company held residential mortgage whole loans with fair value of $200.7 million as of June 30, 2025. As of June 30, 2025, the Company's recourse debt to equity ratio was approximately 1.1x. Dividend On August 5, 2025, the Company declared a dividend of $0.32 per share of common stock, which will be paid on August 29, 2025, to common stockholders of record as of August 22, 2025. Conference Call and Webcast Information The Company will host a live conference call and webcast today, August 5, 2025 at 8:30 a.m. Eastern time. To listen to the live webcast, go to the Investors section of the Company's website at at least 15 minutes prior to the scheduled start time in order to register and install any necessary audio software. To Participate in the Telephone Conference Call: Dial in at least 15 minutes prior to start time. Domestic: 1-844-826-3033 International: 1-412-317-5185 For the conference call playback (which can be accessed through August 19, 2025), dial one of the following numbers: Domestic: 1-844-512-2921 International: 1-412-317-6671 Pass code: 10200567 Non-GAAP Metrics Distributable Earnings is a non‑GAAP measure and is defined as net income (loss) allocable to common stockholders as calculated in accordance with generally accepted accounting principles in the United States of America ('GAAP'), excluding (1) unrealized gains and losses on our aggregate portfolio, (2) impairment losses, (3) extinguishment of debt, (4) non-cash equity compensation expense, (5) the incentive fee earned by Falcons I, LLC, our external manager (our 'Manager'), (6) realized gains or losses on swap terminations and (7) certain other nonrecurring gains or losses. We believe that the presentation of Distributable Earnings provides investors with a useful measure to facilitate comparisons of financial performance among our real estate investment trust ('REIT') peers, but has important limitations. We believe Distributable Earnings as described above helps evaluate our financial performance without the impact of certain transactions but is of limited usefulness as an analytical tool. Therefore, Distributable Earnings should not be viewed in isolation and is not a substitute for net income computed in accordance with GAAP. Our methodology for calculating Distributable Earnings may differ from the methodologies employed by other REITs to calculate the same or similar supplemental performance measures, and as a result, our Distributable Earnings may not be comparable to similar measures presented by other REITs. Distributable Earnings Return on Average Equity is a non-GAAP measure and is defined as annual or annualized Distributable Earnings divided by average total stockholders' equity. We believe that the presentation of Distributable Earnings Return on Average Equity provides investors with a useful measure to facilitate comparisons of financial performance among our REIT peers, but has important limitations. Additionally, we believe Distributable Earnings Return on Average Equity provides investors with additional detail on the Distributable Earnings generated by our invested equity capital. We believe Distributable Earnings Return on Average Equity as described above helps evaluate our financial performance without the impact of certain transactions but is of limited usefulness as an analytical tool. Therefore, Distributable Earnings Return on Average Equity should not be viewed in isolation and is not a substitute for net income computed in accordance with GAAP. Our methodology for calculating Distributable Earnings Return on Average Equity may differ from the methodologies employed by other REITs to calculate the same or similar supplemental performance measures, and as a result, our Distributable Earnings Return on Average Equity may not be comparable to similar measures presented by other REITs. Economic book value is a non-GAAP financial measure of our financial position. To calculate our economic book value, the portions of our non-recourse financing obligation held at amortized cost are adjusted to fair value. These adjustments are also reflected in our end of period total stockholders' equity. Management considers economic book value to provide investors with a useful supplemental measure to evaluate our financial position as it reflects the impact of fair value changes for our legally held retained bonds, irrespective of the accounting model applied for GAAP reporting purposes. Economic book value does not represent and should not be considered as a substitute for book value per share of common stock or stockholders' equity, as determined in accordance with GAAP, and our calculation of this measure may not be comparable to similarly titled measures reported by other companies. Forward-Looking Statements This press release contains certain forward-looking statements that are subject to various risks and uncertainties, including, without limitation, statements relating to the performance of the Company's investments. Forward-looking statements are generally identifiable by use of forward-looking terminology such as 'may,' 'will,' 'should,' 'potential,' 'intend,' 'expect,' 'endeavor,' 'seek,' 'anticipate,' 'estimate,' 'believe,' 'could,' 'project,' 'predict,' 'continue,' or by the negative of these words and phrases or other similar words or expressions. Forward-looking statements are based on certain assumptions, discuss future expectations, describe existing or future plans and strategies, contain projections of results of operations, liquidity and/or financial condition, or state other forward-looking information. The Company's ability to predict future events or conditions or their impact or the actual effect of existing or future plans or strategies is inherently uncertain. Although the Company believes that such forward-looking statements are based on reasonable assumptions, actual results and performance in the future could differ materially from those set forth in or implied by such forward-looking statements. You are cautioned not to place undue reliance on these forward‐looking statements, which reflect the Company's views only as of the date of this press release. Additional information concerning factors that could cause actual results and performance to differ materially from these forward-looking statements is contained from time to time in the Company's filings with the Securities and Exchange Commission. Except as required by applicable law, neither the Company nor any other person assumes responsibility for the accuracy and completeness of the forward‐looking statements. The Company does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Angel Oak Mortgage REIT, Inc. Angel Oak Mortgage REIT, Inc. is a real estate finance company focused on acquiring and investing in first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. The Company's objective is to generate attractive risk-adjusted returns for its stockholders through cash distributions and capital appreciation across interest rate and credit cycles. The Company is externally managed and advised by an affiliate of Angel Oak Capital Advisors, LLC, which, collectively with its affiliates, is a leading alternative credit manager with market leadership in mortgage credit that includes asset management, lending, and capital markets. Additional information about the Company is available at Angel Oak Mortgage REIT, Inc. Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except for share and per share data) As of: December 31, 2024 ASSETS Residential mortgage loans - at fair value $ 200,665 $ 183,064 Residential mortgage loans in securitization trusts - at fair value 1,902,721 1,696,995 RMBS - at fair value 361,884 300,243 Cash and cash equivalents 40,500 40,762 Restricted cash 3,867 2,131 Principal and interest receivable 6,836 8,141 TBA securities and interest rate futures contracts - at fair value — 1,515 Other assets 38,015 36,918 Total assets $ 2,554,488 $ 2,269,769 LIABILITIES AND STOCKHOLDERS' EQUITY LIABILITIES Notes payable $ 118,619 $ 129,459 Non-recourse securitization obligation, collateralized by residential mortgage loans in securitization trusts (see Note 2) 1,767,929 1,593,612 Securities sold under agreements to repurchase 68,062 50,555 Senior unsecured notes 88,601 47,740 TBA securities and interest rate futures contracts - at fair value 4,355 — Due to broker 254,228 201,994 Accrued expenses 2,812 2,291 Accrued expenses payable to affiliate 393 766 Interest payable 2,258 934 Income taxes payable 163 2,785 Management fee payable to affiliate 679 666 Total liabilities $ 2,308,099 $ 2,030,802 Commitments and contingencies STOCKHOLDERS' EQUITY Common stock, $0.01 par value. As of June 30, 2025: 350,000,000 shares authorized, 23,765,202 shares issued and outstanding. As of December 31, 2024: 350,000,000 shares authorized, 23,500,175 shares issued and outstanding. $ 238 $ 234 Additional paid-in capital 463,580 461,057 Accumulated other comprehensive income (loss) (4,661 ) (3,475 ) Retained earnings (deficit) (212,768 ) (218,849 ) Total stockholders' equity $ 246,389 $ 238,967 Total liabilities and stockholders' equity $ 2,554,488 $ 2,269,769 Expand Three Months Ended Six Months Ended June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 ($ in thousands) Average total stockholders' equity $ 248,934 $ 259,565 $ 245,612 $ 258,412 Distributable Earnings Return on Average Equity 4.2 % (3.5 )% 5.5 % 0.4 % Expand
Business Wire
5 minutes ago
- Business Wire
Coinbase Announces Proposed Private Offering of $2.0 Billion of Convertible Senior Notes
Remote-First-Company/PHOENIX--(BUSINESS WIRE)--Coinbase Global, Inc. ('Coinbase') (Nasdaq: COIN) today announced its intention to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible Senior Notes due 2029 (the '2029 notes') and $1.0 billion aggregate principal amount of Convertible Senior Notes due 2032 (the '2032 notes' and, together with the 2029 notes, the 'notes') in a private offering (the 'offering') to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A promulgated under the Securities Act of 1933, as amended (the 'Securities Act'). Coinbase also expects to grant the initial purchasers of each series of notes options to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $150.0 million principal amount of the 2029 notes and $150.0 million principal amount of the 2032 notes. The notes will be senior, unsecured obligations of Coinbase and will accrue interest payable semi-annually in arrears. The 2029 notes will mature on October 1, 2029 and the 2032 notes will mature on October 1, 2032, unless earlier repurchased, converted or, in the case of the 2032 notes, redeemed. The notes will be convertible into cash, shares of Coinbase's Class A common stock, or a combination thereof, at Coinbase's election. The interest rate, initial conversion rate, and other terms of each series of notes are to be determined upon pricing of the offering. In connection with the pricing of the notes, Coinbase expects to enter into privately negotiated capped call transactions relating to each series of notes with one or more of the initial purchasers or their affiliates and/or other financial institutions (the 'option counterparties'). The capped call transactions relating to the 2029 notes will cover, subject to customary adjustments, the number of shares of Coinbase's Class A common stock that will initially underlie the 2029 notes, and the capped call transactions relating to the 2032 notes will cover, subject to customary adjustments, the number of shares of Coinbase's Class A common stock that will initially underlie the 2032 notes. The capped call transactions relating to each series of notes are expected generally to reduce the potential dilution to Coinbase's Class A common stock upon any conversion of the relevant series of notes and/or offset any potential cash payments Coinbase is required to make in excess of the principal amount of converted notes of such series, as the case may be, with such reduction and/or offset subject to a cap. Coinbase has been advised that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to Coinbase's Class A common stock and/or purchase shares of Coinbase's Class A common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Coinbase's Class A common stock or the notes at that time. In addition, Coinbase has been advised that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Coinbase's Class A common stock and/or purchasing or selling Coinbase's Class A common stock or other securities of Coinbase in secondary market transactions following the pricing of the notes and from time to time prior to the maturity of each series of notes (and are likely to do so during the relevant valuation periods under the capped call transactions or following any early conversion of the notes, any repurchase of the notes by Coinbase on any fundamental change repurchase date, any redemption date (with respect to the 2032 notes) or any other date on which the notes are retired by Coinbase, in each case if Coinbase exercises its option to terminate the relevant portion of the capped call transactions). This activity could also cause or avoid an increase or a decrease in the market price of Coinbase's Class A common stock or the notes, which could affect the ability of noteholders to convert the notes and, to the extent the activity occurs during any observation period related to a conversion of a series of notes, it could affect the number of shares of Class A common stock, if any, and value of the consideration that noteholders will receive upon conversion of the applicable notes. Coinbase intends to use a portion of the net proceeds from the offering to pay the cost of the capped call transactions relating to each series of notes. If the initial purchasers exercise their options to purchase additional 2029 notes and/or 2032 notes, Coinbase expects to use a portion of the net proceeds from the sale of such additional notes to enter into additional capped call transactions with the option counterparties with respect to the relevant series of notes as to which the option was exercised. Coinbase intends to use the remainder of the net proceeds from the offering for general corporate purposes, which may include working capital, capital expenditures and investments in and acquisitions of other companies, products or technologies that Coinbase may identify from time to time, as well as to repurchase, repay at maturity, or repurchase or redeem prior to maturity, as applicable, from time to time and subject to market conditions, shares of its Class A common stock and/or its outstanding 0.50% Convertible Senior Notes due 2026, 3.375% Senior Notes due 2028, 3.625% Senior Notes due 2031 and 0.25% Convertible Senior Notes due 2030. The notes will only be offered and sold to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A promulgated under the Securities Act by means of a private offering memorandum. Neither the notes nor the shares of Coinbase's Class A common stock potentially issuable upon conversion of the notes, if any, have been, or will be, registered under the Securities Act or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States, except pursuant to an applicable exemption from such registration requirements. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of the notes or any shares of Class A common stock potentially issuable upon conversion of the notes and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful. About Coinbase Crypto creates economic freedom by ensuring that people can participate fairly in the economy, and Coinbase (Nasdaq: COIN) is on a mission to increase economic freedom for more than 1 billion people. Coinbase is updating the century-old financial system by providing a trusted platform that makes it easy for people and institutions to engage with crypto assets, including trading, staking, safekeeping, spending, and fast, free global transfers. Coinbase also provides critical infrastructure for onchain activity and support builders who share its vision that onchain is the new online. And together with the crypto community, Coinbase advocates for responsible rules to make the benefits of crypto available around the world. Cautionary Statement Regarding Forward-Looking Statements This press release contains 'forward-looking statements' including, among other things, statements relating to the completion, timing, and size of the proposed offering, the granting of options to purchase additional notes, the potential effects of capped call transactions, and the expected use of proceeds from the offering. Statements containing words such as 'could,' 'believe,' 'expect,' 'intend,' 'will,' or similar expressions constitute forward-looking statements. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially, including, but not limited to, whether or not Coinbase will offer the notes or consummate the offering, the final terms of the offering, prevailing market conditions, the anticipated principal amount of the notes, which could differ based upon market conditions, the anticipated use of the net proceeds of the offering, which could change as a result of market conditions or for other reasons, the impact of general economic, industry or political conditions in the United States or internationally, and whether the capped call transactions will become effective. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. For information about other potential factors that could affect Coinbase's business and financial results, please review the 'Risk Factors' described in Coinbase's Annual Report on Form 10-K for the year ended December 31, 2024 and in Coinbase's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Securities and Exchange Commission (the 'SEC') and in Coinbase's other filings with the SEC. Except as may be required by law, Coinbase undertakes no obligation, and does not intend, to update these forward-looking statements after the date of this release.
